PUBLICATIONS - New from Clinica Reports - Market Briefing: The Latest Developments in Drug-Eluting Stents
This article was originally published in Clinica
Drug-eluting stents (DESs) are designed to combat the risk of restenosis. Restenosis, or the re-narrowing of arteries following angioplasty and/or stenting, occurs in 15-40% of bare stent implants. The latest clinical trial results for drug-coated stents give restenosis rates from zero to 4%, generating considerable enthusiasm for the devices throughout the interventional cardiology arena.